⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NRIX News
Nurix Therapeutics, Inc. Common stock
Nurix Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
globenewswire.com
NRIX
Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge
globenewswire.com
GTBP
LYEL
CRBU
SLS
NRIX
Nurix Therapeutics Presents New Data from the Phase 1 Trial of Bexobrutideg (NX-5948) in Waldenström Macroglobulinemia at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition
globenewswire.com
NRIX
Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH) Annual
globenewswire.com
NRIX
Nurix Therapeutics Announces Webcast to Review New and Updated Data from the Phase 1 Clinical Trial of BTK Degrader Bexobrutideg (NX-5948) To Be Presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition
globenewswire.com
NRIX
Nurix Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
globenewswire.com
NRIX
Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors
globenewswire.com
NRIX
Nurix Therapeutics Presents New Translational Data from First-in-Human Clinical Trial of Oral CBL-B Inhibitor NX-1607 Demonstrating Immune Activation and Tumor Microenvironment Remodeling
globenewswire.com
NRIX
Nurix Therapeutics Announces Presentations at the 67th American Society of Hematology (ASH) Annual Meeting
globenewswire.com
NRIX
Nurix Therapeutics to Participate in Upcoming Investor Conferences
globenewswire.com
NRIX